An open label clinical trial to evaluate the efficacy of Sugralo capsule in Madhumeha (Diabetes mellitus type 2) - SDM

Multani Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年1月9日

研究概览

暂无简介。

•1. Patients diagnosed for the first time or Diagnosed cases not taking any medicine for 3 last months.
•2. Patients with cardinal symptoms of Madhumeha described in Ayurveda classics.
•3. Patients having F.B.S. in the range of 126 â?? 200 mg/dl and/or P.P.B.S. between 180-300 mg/dl will be selected for the study.
•4. Patients willing and able to provide signed ICF prior to study will be included in the study.

•1. Patient with type 1 Diabetes mellitus.
•2. Patients with type 2 Diabetes mellitus who are on insulin or oral hypoglycemic drugs.
•3. Patients with FBS >= 200 mg/dl and/or PPBS >= 300 mg/dl.
•4. Patients of Gestational Diabetes and Juvenile Diabetes.
•5. Patient having Type-II DM with any other serious systemic disease.
•6. Patients with complications like cardiac disorder, diabetic foot, Nephropathy and other secondary complications.
•7. Diabetes Mellitus produced due to other illnesses like Acromegaly, Cushingâ??s syndrome, pancreatic disorders etc.
•8. Individuals not willing to provide written Informed Consent Form.
•9. Individuals participating in any other clinical trial.
•10. Pregnant or lactating females.

发起方

Multani Pharmaceuticals Ltd